Bayer receives UK MHRA approval for Lynkuet to treat moderate to severe vasomotor symptoms associated with menopause: Berlin Saturday, July 12, 2025, 10:00 Hrs [IST] Bayer announc ...

Bayer, a global enterprise with core competencies in the life science fields of agriculture and healthcare, announced the ...

(Reuters) -The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased by an experimental non-hormonal drug being developed by Bayer, ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...

The Ministry of Business and Made in Italy has awarded Bayer Italia the "Excellence of the Production System and Made in ...

Bayer launches Felujit fungicide for paddy cultivation, offering superior protection against sheath blight with dual-action ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared the oral neurokinin (NK) 1 and 3 antagonist, under the Lynkuet brand name, for the treatment of moderate to severe vasomotor ...

Berlin: Bayer has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA, regulatory authority ...

Bayer seeks European marketing authorization for investigational contrast agent, gadoquatrane: Berlin Friday, July 11, 2025, 11:00 Hrs [IST] Bayer announced the submission of a ma ...

DEKALB and Asgrow are rolling out 43 new corn and soybean products for 2026 featuring advanced pest and disease protection.

DKSH Business Unit Healthcare, a Strategic Healthcare Solutions Partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device ...